Tredje AP fonden Has $1.28 Million Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Tredje AP fonden lessened its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 50.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 9,364 shares of the company's stock after selling 9,364 shares during the quarter. Tredje AP fonden's holdings in Neurocrine Biosciences were worth $1,278,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Louisiana State Employees Retirement System increased its holdings in Neurocrine Biosciences by 0.4% in the fourth quarter. Louisiana State Employees Retirement System now owns 28,100 shares of the company's stock valued at $3,836,000 after purchasing an additional 100 shares during the last quarter. Metis Global Partners LLC increased its holdings in Neurocrine Biosciences by 4.3% in the fourth quarter. Metis Global Partners LLC now owns 2,548 shares of the company's stock valued at $348,000 after purchasing an additional 104 shares during the last quarter. Commerce Bank increased its holdings in Neurocrine Biosciences by 2.6% in the third quarter. Commerce Bank now owns 4,199 shares of the company's stock valued at $484,000 after purchasing an additional 108 shares during the last quarter. Tokio Marine Asset Management Co. Ltd. increased its holdings in Neurocrine Biosciences by 2.7% in the third quarter. Tokio Marine Asset Management Co. Ltd. now owns 4,302 shares of the company's stock valued at $496,000 after purchasing an additional 113 shares during the last quarter. Finally, Brooklyn Investment Group increased its holdings in Neurocrine Biosciences by 99.1% in the fourth quarter. Brooklyn Investment Group now owns 231 shares of the company's stock valued at $32,000 after purchasing an additional 115 shares during the last quarter. Institutional investors own 92.59% of the company's stock.

Remove Ads

Insider Activity

In other news, CFO Matt Abernethy sold 1,283 shares of Neurocrine Biosciences stock in a transaction on Friday, January 31st. The stock was sold at an average price of $152.87, for a total value of $196,132.21. Following the transaction, the chief financial officer now owns 32,681 shares in the company, valued at approximately $4,995,944.47. This trade represents a 3.78 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Kevin Charles Gorman sold 146,105 shares of Neurocrine Biosciences stock in a transaction on Monday, January 27th. The shares were sold at an average price of $149.46, for a total value of $21,836,853.30. Following the completion of the transaction, the director now owns 514,596 shares in the company, valued at approximately $76,911,518.16. The trade was a 22.11 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 233,178 shares of company stock valued at $33,906,594 over the last three months. Insiders own 4.30% of the company's stock.

Neurocrine Biosciences Stock Performance

NASDAQ NBIX traded up $0.61 during trading hours on Wednesday, hitting $110.31. 910,078 shares of the company traded hands, compared to its average volume of 957,454. Neurocrine Biosciences, Inc. has a twelve month low of $105.18 and a twelve month high of $157.98. The stock has a market capitalization of $11.00 billion, a price-to-earnings ratio of 33.53, a P/E/G ratio of 0.77 and a beta of 0.35. The business's 50-day moving average is $128.62 and its 200-day moving average is $125.47.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The company reported $1.00 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.62 by ($0.62). Neurocrine Biosciences had a net margin of 14.49% and a return on equity of 13.38%. Analysts predict that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current year.

Neurocrine Biosciences declared that its Board of Directors has initiated a stock buyback plan on Friday, February 21st that allows the company to repurchase $500.00 million in outstanding shares. This repurchase authorization allows the company to buy up to 4.2% of its stock through open market purchases. Stock repurchase plans are often an indication that the company's board believes its stock is undervalued.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on NBIX. Needham & Company LLC reiterated a "hold" rating on shares of Neurocrine Biosciences in a report on Friday, February 7th. Barclays increased their price target on Neurocrine Biosciences from $160.00 to $165.00 and gave the stock an "overweight" rating in a report on Monday, December 23rd. HC Wainwright restated a "buy" rating and issued a $185.00 price target on shares of Neurocrine Biosciences in a report on Friday, February 21st. StockNews.com upgraded Neurocrine Biosciences from a "buy" rating to a "strong-buy" rating in a report on Wednesday, March 12th. Finally, Royal Bank of Canada lowered their price target on Neurocrine Biosciences from $154.00 to $148.00 and set a "sector perform" rating for the company in a report on Friday, February 7th. Five investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $165.24.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.